BIIB Biogen
FY2025 10-K
Biogen (BIIB) filed its fiscal year 2025 10-K annual report with the SEC on Feb 6, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Global biopharmaceutical company developing and commercializing therapies primarily for neurology, specialized immunology, and rare diseases
- • New or emphasized segment: Expanded collaboration with Genentech on multiple anti-CD20 therapies including recently approved GAZYVA for lupus nephritis in Oct 2025
Management Discussion & Analysis
- • No specific revenue or YoY change figures disclosed in provided text
- • No profitability or margin figures mentioned
Risk Factors
- • Regulatory risk: IRA Medicare Part D redesign caused $90 million 2025 revenue loss, impacting SKYCLARYS and MS portfolio with future pricing enforcement uncertainty
- • Geopolitical risk: Russia-Ukraine conflict may disrupt supply; revenues from Russia, Ukraine, Middle East each <2.0% of total revenue in 2023-2025
Financial SummaryXBRL
Revenue
$9.9B
Net Income
$1.3B
Net Margin
13.1%
ROE
7.1%
Total Assets
$29.4B
EPS (Diluted)
$8.79
Operating Cash Flow
$2.2B
Source: XBRL data from Biogen FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Biogen
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.